Answers are grounded in this paper and cite their sources.
The article presents a case of development of bone tissue damage as a manifestation of toxicity against the background of differentiation therapy of 13-cis-Retinoic acid in a patient with neuroblastoma (NB) of a high-risk group. This clinical example is of interest as a model of a differential diagnosis of metastatic osseous lesion in patients with disseminated NB and a rare variant of bone toxicity during specific therapy.
No takes yet. Share an insight, caveat, or question.
Sagoyan et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: